Speakers: Aman Chauhan, MD and Daniel Morgensztern, MD
This educational program is designed to enhance the knowledge and competence of healthcare professionals caring for patients with neuroendocrine lung cancers. It provides an overview of DLL3 biology in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma of the lung (LCNEC-L), the scientific rationale supporting DLL3 as a target for bispecific T-cell engager (BiTE) therapies, and the mechanism by which these agents redirect T cells. The program also reviews emerging clinical evidence on the efficacy, safety, and dosing of DLL3-targeted BiTEs in extensive-stage SCLC (ES-SCLC) and LCNEC-L, while equipping participants with practical strategies to prevent and manage treatment-related adverse events (TRAEs).
This activity is designed to meet the educational needs of oncologists and oncology advanced practice practitioners (APPs).